1001415-66-2

1001415-66-2 structure

Name: Remimazolam benzenesulfonate
Chemical Name: Remimazolam benzenesulfonate
CAS Number: 1001415-66-2
Molecular Formula: C₂₇H₂₅BrN₄O₅S
Molecular Weight: 597.48000
Catalog: Signaling Pathways Membrane Transporter/Ion Channel GABA Receptor
Create Date: 2018-04-13 08:00:00
Modify Date: 2024-01-02 11:15:30
Remimazolam benzenesulfonate is a GABA agonist。Target: GABA ReceptorRemimazolam acts on GABA receptor, specifically GABA-alpha. Remimazolam is a new drug innovation in anesthesia. Remimazolam combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil. Remimazolam acts on GABA receptors like midazolam and has organ-independent metabolism like remifentanil. Remimazolam is likely to be the sedative of the future, as preliminary phase II trials have shown minimal residual effects on prolonged infusions. Remimazolam has potential to be used as a sedative in ICU and as a novel agent for procedural sedation.

Name	Remimazolam benzenesulfonate
Synonyms	CN-7056 benzenesulfonate methyl (S)-3-(8-bromo-1-methyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,2-a][1,4]diazepin-4-yl)propanoate benzenesulfonate Remimazolam (benzenesulfonate)

Description	Remimazolam benzenesulfonate is a GABA agonist。Target: GABA ReceptorRemimazolam acts on GABA receptor, specifically GABA-alpha. Remimazolam is a new drug innovation in anesthesia. Remimazolam combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil. Remimazolam acts on GABA receptors like midazolam and has organ-independent metabolism like remifentanil. Remimazolam is likely to be the sedative of the future, as preliminary phase II trials have shown minimal residual effects on prolonged infusions. Remimazolam has potential to be used as a sedative in ICU and as a novel agent for procedural sedation.
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> GABA Receptor Signaling Pathways >> Neuronal Signaling >> GABA Receptor Research Areas >> Neurological Disease
References	[1]. Goudra BG, et al. Remimazolam: The future of its sedative potential. Saudi J Anaesth. 2014 Jul;8(3):388-391.